NCI SBIR program director Kory Hallett will be providing an overview of the NCI small business funding opportunities at a webinar hosted by American Society for Biochemistry and Molecular Biology (ASBMB). Kory will be joined by current STTR awardee Sami Kanaan (Principal, Chimerocyte), who will be sharing his personal experience going from an applicant to an awardee. You will also learn about different types of applicant and awardee resources available at NCI SBIR Development Center.
Participants can submit questions prior to the webinar. Please contact ASBMB (contact to be updated soon) with your questions, and the two speakers will be answering them at the end of the webinar. For questions about this event, please contact email@example.com.
Kory Hallett, Ph.D.
Kory Hallett is a Program Manager in the Small Business Innovation Research Development Center at the National Cancer Institute. Kory manages program evaluation for the Development Center, and serves as a program officer to SBIR and STTR grants in the areas of immunology, immunotherapy, and monoclonal antibody technology. She also participates in the Center's many initiatives to support the development of innovative cancer technologies. Kory initially joined the NCI SBIR Development Center in 2014 as a Science & Technology Policy Fellow with the American Association for the Advancement of Science (AAAS).
Kory received her doctorate in Cell and Molecular Biology in 2009 from the University of Nevada, Reno. She completed a postdoctoral research fellowship at the University of Wisconsin-Madison, where she worked in a translational lab researching monoclonal antibody-based therapeutics for pediatric neuroblastoma.
Sami Kanaan, Ph.D.
Dr. Kanaan’s research is focused on the immunogenetics of autoimmune diseases and cancer, with an emphasis on the HLA that is key to the self-vs.-non-self immune recognition, and its effects whether inherited (Mendelian) or non-inherited but naturally acquired from pregnancy-derived cell exchange. His work in developing a portfolio of highly sensitive and polymorphism-(HLA and other genes)-specific qPCR technology and his wish to transfer it into a clinical application has led to start up the biotech company Chimerocyte, Inc. Chimerocyte aims at the development of a complete panel of assays to detect and quantify allogeneic cells (i.e. chimerism) at levels of sensitivities that may have life-saving consequences in the context of leukemia-treating allogeneic hematopoietic stem cell transplantation.